A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease

Trial Profile

A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2017

At a glance

  • Drugs Budesonide (Primary)
  • Indications IgA nephropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms NEFIGAN
  • Sponsors Pharmalink AB
  • Most Recent Events

    • 04 Jun 2017 Results published in a Pharmalink AB media release.
    • 04 Jun 2017 According to a Pharmalink AB media release, results from this trial were presented at the 2017 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) conference.
    • 31 May 2017 According to a Pharmalink AB media release, dat from this study will be presented at upcoming European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top